INT183618

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.15
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 12
Disease Relevance 2.22
Pain Relevance 1.21

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (TMED4) endoplasmic reticulum (TMED4) signal transducer activity (TMED4)
Anatomy Link Frequency
median nerve 1
ERD 1
TMED4 (Homo sapiens)
Pain Link Frequency Relevance Heat
Somatosensory cortex 110 100.00 Very High Very High Very High
agonist 40 99.02 Very High Very High Very High
primary somatosensory cortex 68 98.72 Very High Very High Very High
magnetoencephalography 48 94.68 High High
Codeine 14 70.56 Quite High
Analgesic 7 67.24 Quite High
Morphine 7 65.92 Quite High
GABA receptor 1 60.76 Quite High
Opioid 1 59.88 Quite High
GABAergic 6 58.52 Quite High
Disease Link Frequency Relevance Heat
Breast Cancer 34 99.00 Very High Very High Very High
Attention Deficit Hyperactivity Disorder 190 98.80 Very High Very High Very High
Cancer 56 96.12 Very High Very High Very High
Endometriosis (extended) 64 95.64 Very High Very High Very High
Cognitive Disorder 14 78.12 Quite High
Osteoporosis 42 71.92 Quite High
Postmenopausal Osteoporosis 4 70.00 Quite High
Targeted Disruption 5 65.36 Quite High
Toxicity 9 59.00 Quite High
Apoptosis 58 50.00 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The ability that isoflavones have to mimic oestrogen molecules in their capacity to bind to estrogens receptors (ERs) is most evident in genistein and daidzein and their derivatives.
ERs Binding (bind) of
1) Confidence 0.15 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2852849 Disease Relevance 0.16 Pain Relevance 0
The increase of dosage can signify an increase of the amount that can be related to the risk, i.e., molecules that have a preferential binding to alpha-ERs.
ERs Binding (binding) of
2) Confidence 0.13 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2852849 Disease Relevance 0.14 Pain Relevance 0.27
In this paper we used the Fokialakis et al., ERs affinity binding for estradiol for some isoflavones but the some theoretical calculations can be done with other affinities published.
ERs Binding (binding) of
3) Confidence 0.13 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2852849 Disease Relevance 0.06 Pain Relevance 0
To do the theoretical calculation [14] these amounts of isoflavones were multiplied by the “ERs binding affinities” based on the values obtained in literature [10].
ERs Binding (affinities) of
4) Confidence 0.10 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2852849 Disease Relevance 0.22 Pain Relevance 0
Daidzein and genistein do not have the same binding affinity to alpha- and/or beta-ERs [10].
ERs Binding (affinity) of
5) Confidence 0.10 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2852849 Disease Relevance 0.17 Pain Relevance 0
Also known and frequently mentioned by several authors is that the linkage of oestrogens or oestrogenic compounds to alpha-ERs could be dangerous with breast cancers because it could aid the proliferation of damaged DNA in tumours [15,16].
ERs Binding (linkage) of associated with cancer and breast cancer
6) Confidence 0.10 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2852849 Disease Relevance 0.20 Pain Relevance 0
For example, in the first calculations (Table 2) the determined risk is 1.9 and 2.1% (trial 1 and trial 2) but the amounts of compounds capable to be bound to alpha-ERs are different.
ERs Binding (bound) of
7) Confidence 0.10 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2852849 Disease Relevance 0.38 Pain Relevance 0
Estrogens diffuse into cells and binds to the ERs, triggering ER dimerization as well as a specific conformational change (Jensen 1991).
ERs Binding (binds) of
8) Confidence 0.03 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2684086 Disease Relevance 0.13 Pain Relevance 0.03
Among the specific hormone receptors involved, two estrogen receptors (ERs) are of particular interest: ER-?
ERs Binding (two) of
9) Confidence 0.03 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1143573 Disease Relevance 0 Pain Relevance 0
Accordingly, our aim was to characterize ERD and ERS in the alpha and beta bands in SI and SII in response to randomly and predictably presented electrical stimulation of the median nerve in adults with and without ADHD.
ERS Binding (characterize) of in ERD associated with somatosensory cortex, primary somatosensory cortex and attention deficit hyperactivity disorder
10) Confidence 0.02 Published 2008 Journal Behav Brain Funct Section Body Doc Link PMC2266931 Disease Relevance 0.42 Pain Relevance 0.33
Following the suppression, the final phase of activity demonstrated a rebound of ERS specific to the beta band that began approximately 400 ms after median nerve stimulation and lasted for about 1200 ms (Figure 2A).
ERS Binding (rebound) of in median nerve
11) Confidence 0.02 Published 2008 Journal Behav Brain Funct Section Body Doc Link PMC2266931 Disease Relevance 0.22 Pain Relevance 0.35
agonists, making it unlikely that all three classes will interact these alternative ERs.
ERs Binding (interact) of associated with agonist
12) Confidence 0.01 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2910705 Disease Relevance 0.14 Pain Relevance 0.23

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox